Jun Hakamata
Overview
Explore the profile of Jun Hakamata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishikawa E, Yokoyama Y, Chishima H, Kasai H, Kuniyoshi O, Kimura M, et al.
Invest New Drugs
. 2023 Jan;
41(1):122-133.
PMID: 36637703
Background: Potential novel strategies for adverse event (AE) management of osimertinib therapy, including therapeutic drug monitoring and the use of biomarkers, have not yet been fully investigated. This study aimed...
2.
Ishikawa E, Yokoyama Y, Chishima H, Kuniyoshi O, Sato I, Nakaya N, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2022 Apr;
1199:123245.
PMID: 35436724
Reports on the therapeutic drug monitoring (TDM) of second- and third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer patients are limited and are required to...
3.
Hakamata J, Nakada H, Muramatsu H, Masuzawa K, Terai H, Ikemura S, et al.
Clin Case Rep
. 2021 Sep;
9(8).
PMID: 34466232
Lorlatinib can cause visual and auditory hallucinations. And, it is necessary to keep in mind that hallucinations can persist even after discontinuation in patients who develop hallucinations while receiving lorlatinib.
4.
Sakai C, Shimokawa M, Iihara H, Fujita Y, Ikemura S, Hirose C, et al.
Oncologist
. 2021 Apr;
26(6):e1066-e1072.
PMID: 33811782
Background: Olanzapine is an inexpensive and durable agent for the treatment of chemotherapy-induced nausea and vomiting and is also superior to neurokinin-1 receptor antagonists in the control of nausea. This...
5.
Hakamata J, Kaneko Y, Shimizu M, Yamaoka K, Maruyama J, Takeuchi T, et al.
Biol Pharm Bull
. 2018 Sep;
41(9):1414-1422.
PMID: 30175777
Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it...
6.
Hashiguchi M, Hakamata J, Shimizu M, Maruyama J, Shiga T, Mochizuki M
Int J Clin Pharmacol Ther
. 2018 Apr;
56(7):310-320.
PMID: 29701171
Objective: To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR...
7.
Hakamata J, Hashiguchi M, Kaneko Y, Yamaoka K, Shimizu M, Maruyama J, et al.
Mod Rheumatol
. 2017 Dec;
28(4):611-620.
PMID: 29252093
Objectives: Methotrexate (MTX) is used as first-line treatment of rheumatoid arthritis (RA) worldwide. Large interindividual differences in MTX effectiveness and safety occur, and the most frequent adverse reaction is hepatotoxicity,...
8.
Hashiguchi M, Shimizu M, Hakamata J, Tsuru T, Tanaka T, Suzaki M, et al.
J Pharm Health Care Sci
. 2016 Dec;
2:35.
PMID: 27980801
Background: Methotrexate (MTX) is currently the anchor drug widely used worldwide in the treatment of rheumatoid arthritis (RA). However, the therapeutic response to MTX has been shown to vary widely...
9.
Hashiguchi M, Tsuru T, Miyawaki K, Suzaki M, Hakamata J, Shimizu M, et al.
J Pharm Health Care Sci
. 2016 Jun;
2:13.
PMID: 27274398
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammatory status, joint destruction, disability, and pain. Methotrexate (MTX) has been confirmed to reduce disease activity and delay...
10.
Hashiguchi M, Tanaka T, Shimizu M, Tsuru T, Chiyoda T, Miyawaki K, et al.
J Clin Pharmacol
. 2016 May;
56(12):1563-1569.
PMID: 27146084
Sex differences in the prevalence of autoimmune diseases such as rheumatoid arthritis (RA) are well known, but little is known about those differences in relation to therapeutic response. Reduced folate...